Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to
evaluate the safety of CD19 CAR-T therapy for patients with relapsed or refractory
Neuromyelitis Optica, and to evaluate the pharmacokinetics of CD19 CAR-T in patients.